Cobra Biologics Limited
Cobra Biologics Limited, a leading contract development and manufacturing organisation (CDMO), is headquartered in the United Kingdom. Established in 2003, Cobra has made significant strides in the biopharmaceutical industry, specialising in the production of plasmid DNA, viral vectors, and cell line development. With operational facilities in both the UK and Sweden, the company serves a global clientele, providing tailored solutions for gene therapy and vaccine development. Cobra's core offerings include high-quality plasmid DNA and viral vector production, distinguished by their commitment to stringent quality standards and regulatory compliance. The company has achieved notable milestones, including successful collaborations with prominent biotech firms, solidifying its position as a trusted partner in the biomanufacturing landscape. With a focus on innovation and customer-centric services, Cobra Biologics continues to play a pivotal role in advancing biopharmaceutical development.
DitchCarbon Score
How does Cobra Biologics Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cobra Biologics Limited's score of 41 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cobra Biologics Limited's reported carbon emissions
Cobra Biologics Limited, headquartered in Great Britain, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their carbon footprint or climate strategy. However, the absence of data may indicate a need for further transparency in their environmental impact and sustainability efforts. As the industry increasingly prioritises climate action, it is essential for companies like Cobra Biologics to establish and communicate clear emissions reduction targets and commitments to align with global climate standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cobra Biologics Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
